{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:49:13Z","timestamp":1695577753594},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.crohns.2013.02.016","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T12:46:06Z","timestamp":1363610766000},"page":"958-967","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials"],"prefix":"10.1093","volume":"7","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majin","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopal","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2013.02.016_bb0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2013.02.016_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"The P S I. Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.02.016_bb0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"The Crohn's disease c A S G. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.02.016_bb0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0040","series-title":"Humira [package insert]","year":"2011"},{"key":"10.1016\/j.crohns.2013.02.016_bb0045","series-title":"Remicade [package insert]","year":"2011"},{"key":"10.1016\/j.crohns.2013.02.016_bb0050","series-title":"Cimzia [package insert]","year":"2011"},{"key":"10.1016\/j.crohns.2013.02.016_bb0055","series-title":"Remicade [summary of product characteristics]","year":"2009"},{"key":"10.1016\/j.crohns.2013.02.016_bb0060","series-title":"Humira [summary of product characteristics]","year":"2012"},{"key":"10.1016\/j.crohns.2013.02.016_bb0065","series-title":"Remicade [summary of product characteristics]","year":"2011"},{"key":"10.1016\/j.crohns.2013.02.016_bb0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0205","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ibd.20275","article-title":"Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies","volume":"14","author":"Schoepfer","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0009-8981(85)90219-0","article-title":"C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders","volume":"148","author":"Shine","year":"1985","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.crohns.2013.02.016_bb0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","article-title":"C-reactive protein as a marker for inflammatory bowel disease","volume":"10","author":"Vermeire","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0110","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0210","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.MIB.0000217768.75519.32","article-title":"Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease","volume":"12","author":"Hlavaty","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0125","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn's disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0135","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ibd.20036","article-title":"Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark","volume":"13","author":"Jess","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0140","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/ajg.2010.98","article-title":"Editorial: improved efficacy of biological maintenance therapy in \u201cearly\u201d compared with \u201clate\u201d Crohn's disease: strike while the iron is hot with anti-TNF agents?","volume":"105","author":"Ananthakrishnan","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0145","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0155","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn's disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.02.016_bb0160","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00054725-199712000-00004","article-title":"An evaluation of utility measurement in Crohn's disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0165","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn's disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.02.016_bb0170","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.crohns.2013.02.016_bb0175","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2013.02.016_bb0220","article-title":"High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?","author":"Kiss","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.02.016_bb0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2036.2005.02314.x","article-title":"Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status","volume":"21","author":"Barratt","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.02.016_bb0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cgh.2011.01.019","article-title":"Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease","volume":"9","author":"Bruining","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2013.02.016_bb0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1023\/B:DDAS.0000020506.84248.f9","article-title":"IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior","volume":"49","author":"Minderhoud","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2013.02.016_bb0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1572-0241.2002.05475.x","article-title":"Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Simren","year":"2002","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/12\/958\/13071947\/7-12-958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T02:52:55Z","timestamp":1562813575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2013.02.016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1873994613000986"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2013.02.016","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}